“In the second quarter of 2025, we continued to build on the strong momentum established with the announcement of statistically significant reversal of cirrhosis due to MASH in the Phase 2b SYMMETRY study, supported by the peer-reviewed publication of 96-week results in the New England Journal of Medicine and additional data presentations that reinforce the anti-fibrotic activity of EFX across all stages of MASH,” said Andrew Cheng, president and CEO. “We look forward to reporting preliminary results of our first Phase 3 trial, SYNCHRONY Real-World, in the first half of 2026 as well as a readout of SYNCHRONY Histology in the first half of 2027.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKTX:
- Akari Therapeutics releases ‘What This Means’ segment for investors
- Akari Therapeutics reiterates commitment to research on PH1
- Akari Therapeutics ‘just getting started,’ initiated with a Buy at Maxim
- Akari Therapeutics initiated with a Buy at Maxim
- Akari Therapeutics Shareholders Approve Key AGM Resolutions